Fig. 1From: Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparisonSchematic diagram of the clinical application of bispecific antibodies and ICI combination. a Landscape of clinical trials of BSABs in human cancers. LAG-3, lymphocyte activation gene-3. b Landscape of Clinical trials of ICI combination therapies in human cancersBack to article page